• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

RUNX3与H3K27me3共表达预示手术切除的I期且未接受术后化疗的非小细胞肺癌患者预后更佳。

RUNX3/H3K27me3 Co-Expression Defines a Better Prognosis in Surgically Resected Stage I and Postoperative Chemotherapy-Naive Non-Small-Cell Lung Cancer.

作者信息

Chen Xiaohui, Deng Yujie, Huang Chuanzhong, Shi Yi, Lu Jianping, Weng Guibin, Zhu Weifeng, Zhu Kunshou, Chen Junqiang, Li Jiancheng

机构信息

Department of Thoracic Surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, Fujian 350014, China.

College of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.

出版信息

J Oncol. 2022 Mar 24;2022:5752263. doi: 10.1155/2022/5752263. eCollection 2022.

DOI:10.1155/2022/5752263
PMID:35368900
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8970863/
Abstract

The purpose of this study is to investigate the significance of RUNX3/H3K27me3 co-expression in surgically resected non-small-cell lung cancer (NSCLC) patients. Using tissue microarray (TMA), immunohistochemistry, fluorescent double immunostaining, and western blotting, 208 NSCLC and 5 benign pulmonary patients were studied of their expression of runt-related transcription factor 3 (RUNX3), trimethylated histone H3 at lysine 27 (H3K27me3), enhancer of zeste homolog 2 (EZH2), and Ki-67. Apoptotic index in cancerous tissue was evaluated via TdT-mediated dUTP-biotin nick end labeling (TUNEL). The correlation between clinicopathologic parameters and overall survival was determined by Cox regression and Kaplan-Meier survival estimates and log-rank test. GEPIA and KM plotter were used for validation of some survival analyses. As a result, together with other regular prognostic factors, RUNX3/H3K27me3 co-expression was found to be closely correlated with better prognosis in either pTNM-I or POCT-naive NSCLC patients, which might partially result from a higher cancerous apoptotic index. In conclusion, RUNX3/H3K27me3 co-expression defined some specific NSCLC population with better prognosis and longer OS and could probably be used as a biomarker in the prediction of better postoperative outcomes.

摘要

本研究旨在探讨RUNX3/H3K27me3共表达在接受手术切除的非小细胞肺癌（NSCLC）患者中的意义。利用组织芯片（TMA）、免疫组织化学、荧光双重免疫染色和蛋白质印迹法，对208例NSCLC患者和5例良性肺病患者的 runt相关转录因子3（RUNX3）、赖氨酸27位三甲基化组蛋白H3（H3K27me3）、zeste同源物2增强子（EZH2）和Ki-67的表达进行了研究。通过末端脱氧核苷酸转移酶介导的dUTP生物素缺口末端标记法（TUNEL）评估癌组织中的凋亡指数。通过Cox回归、Kaplan-Meier生存估计和对数秩检验确定临床病理参数与总生存之间的相关性。使用GEPIA和KM plotter对一些生存分析进行验证。结果发现，与其他常规预后因素一起，RUNX3/H3K27me3共表达在pTNM-I期或初治NSCLC患者中与较好的预后密切相关，这可能部分归因于较高的癌组织凋亡指数。总之，RUNX3/H3K27me3共表达定义了一些预后较好、总生存期较长的特定NSCLC人群，并且可能用作预测更好术后结果的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/6b7295a6a67d/JO2022-5752263.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/b5c210fc5c5d/JO2022-5752263.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/f86438544fc4/JO2022-5752263.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/34567af9dc09/JO2022-5752263.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/b714c8cc5aec/JO2022-5752263.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/2b9641e17ce6/JO2022-5752263.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/6d37b7cafa5e/JO2022-5752263.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/35f56e4611be/JO2022-5752263.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/33d9a2b9606f/JO2022-5752263.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/99afdeeee8dc/JO2022-5752263.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/bffed5af1b4e/JO2022-5752263.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/6b7295a6a67d/JO2022-5752263.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/b5c210fc5c5d/JO2022-5752263.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/f86438544fc4/JO2022-5752263.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/34567af9dc09/JO2022-5752263.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/b714c8cc5aec/JO2022-5752263.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/2b9641e17ce6/JO2022-5752263.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/6d37b7cafa5e/JO2022-5752263.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/35f56e4611be/JO2022-5752263.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/33d9a2b9606f/JO2022-5752263.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/99afdeeee8dc/JO2022-5752263.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/bffed5af1b4e/JO2022-5752263.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d674/8970863/6b7295a6a67d/JO2022-5752263.011.jpg

相似文献

1
RUNX3/H3K27me3 Co-Expression Defines a Better Prognosis in Surgically Resected Stage I and Postoperative Chemotherapy-Naive Non-Small-Cell Lung Cancer.RUNX3与H3K27me3共表达预示手术切除的I期且未接受术后化疗的非小细胞肺癌患者预后更佳。
J Oncol. 2022 Mar 24;2022:5752263. doi: 10.1155/2022/5752263. eCollection 2022.
2
High expression of trimethylated histone H3 at lysine 27 predicts better prognosis in non-small cell lung cancer.组蛋白 H3 赖氨酸 27 三甲基化水平高预示非小细胞肺癌患者预后较好。
Int J Oncol. 2013 Nov;43(5):1467-80. doi: 10.3892/ijo.2013.2062. Epub 2013 Aug 20.
3
Loss of expression rather than cytoplasmic mislocalization of RUNX3 predicts worse outcome in non-small cell lung cancer.RUNX3表达缺失而非细胞质定位错误预示着非小细胞肺癌的预后更差。
Oncol Lett. 2018 Apr;15(4):5043-5055. doi: 10.3892/ol.2018.7993. Epub 2018 Feb 8.
4
Analysis of H3K27me3 expression and DNA methylation at CCGG sites in smoking and non-smoking patients with non-small cell lung cancer and their clinical significance.非小细胞肺癌吸烟与非吸烟患者中H3K27me3表达及CCGG位点DNA甲基化分析及其临床意义
Oncol Lett. 2018 May;15(5):6179-6188. doi: 10.3892/ol.2018.8100. Epub 2018 Feb 21.
5
Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma.RUNX3表达缺失是弥漫性大B细胞淋巴瘤的一个独立不良预后因素。
Leuk Lymphoma. 2017 Jan;58(1):179-184. doi: 10.1080/10428194.2016.1180686. Epub 2016 May 17.
6
Enhancer of zeste homolog 2 is a negative prognostic biomarker and correlated with immune infiltrates in meningioma.zeste 同源物 2 增强子是一种负性预后生物标志物，与脑膜瘤中的免疫浸润相关。
Front Neurosci. 2022 Nov 30;16:1076530. doi: 10.3389/fnins.2022.1076530. eCollection 2022.
7
Combined Detection of RUNX3 and EZH2 in Evaluating Efficacy of Neoadjuvant Therapy and Prognostic Value of Middle and Low Locally Advanced Rectal Cancer.联合检测RUNX3和EZH2评估新辅助治疗疗效及中低位局部进展期直肠癌的预后价值
Front Oncol. 2022 Feb 24;12:713335. doi: 10.3389/fonc.2022.713335. eCollection 2022.
8
[RUNX3 promoter hypermethylation and prognosis of early surgically resected non-small cell lung cancers].[RUNX3启动子高甲基化与早期手术切除的非小细胞肺癌的预后]
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Jul;36(7):650-4. doi: 10.3969/j.issn.1672-7347.2011.07.012.
9
Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.EZH2 是一种非小细胞肺癌的新型预后生物标志物。
Cancer. 2012 Mar 15;118(6):1599-606. doi: 10.1002/cncr.26441. Epub 2011 Aug 11.
10
Mutually exclusive expression of EZH2 and H3K27me3 in non-small cell lung carcinoma.EZH2与H3K27me3在非小细胞肺癌中的相互排斥表达。
Pathol Res Pract. 2022 Oct;238:154071. doi: 10.1016/j.prp.2022.154071. Epub 2022 Aug 12.

引用本文的文献

1
Single-Cell RNA Sequencing Reveals Potential Mechanism of RUNX3 Reshaping Tumor Microenvironment in Non-small-cell Lung Cancer.单细胞RNA测序揭示RUNX3重塑非小细胞肺癌肿瘤微环境的潜在机制
Ann Surg Oncol. 2025 Sep 7. doi: 10.1245/s10434-025-18034-w.
2
Decoding bronchopulmonary dysplasia in premature infants through an epigenetic lens.从表观遗传学角度解读早产儿支气管肺发育不良
Front Med (Lausanne). 2025 Apr 3;12:1531169. doi: 10.3389/fmed.2025.1531169. eCollection 2025.

本文引用的文献

1
Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.分子检测指导下的非小细胞肺癌患者的预后和分期改善。
Future Oncol. 2021 Dec;17(34):4785-4795. doi: 10.2217/fon-2021-0517. Epub 2021 Aug 26.
2
Adjuvant treatment in lung cancer.肺癌的辅助治疗。
J Clin Transl Res. 2021 Apr 16;7(2):175-184. eCollection 2021 Apr 22.
3
Epigenome-wide scan identifies differentially methylated regions for lung cancer using pre-diagnostic peripheral blood.基于外周血的肺癌表观基因组全扫描鉴定出差异甲基化区域
Epigenetics. 2022 Apr;17(4):460-472. doi: 10.1080/15592294.2021.1923615. Epub 2021 May 19.
4
The addition of radiotherapy to adjuvant chemotherapy has a combinatorial effect in pN2 non-small cell lung cancer only with extranodal invasion or multiple N2 metastasis.仅在伴有结外侵犯或多发N2转移的pN2期非小细胞肺癌中，放疗联合辅助化疗具有协同作用。
Lung Cancer. 2021 May;155:94-102. doi: 10.1016/j.lungcan.2021.03.011. Epub 2021 Mar 16.
5
Cancer Statistics, 2021.癌症统计数据，2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
6
Postoperative radiotherapy for pathological stage IIIA-N2 non-small cell lung cancer with positive surgical margins.术后放疗用于切缘阳性的病理 IIIA-N2 期非小细胞肺癌。
Thorac Cancer. 2021 Jan;12(2):227-234. doi: 10.1111/1759-7714.13749. Epub 2020 Nov 27.
7
Elevated expression of RUNX3 co-expressing with EZH2 in esophageal cancer patients from India.在来自印度的食管癌患者中，RUNX3与EZH2共表达的水平升高。
Cancer Cell Int. 2020 Sep 10;20:445. doi: 10.1186/s12935-020-01534-y. eCollection 2020.
8
Oncogenic RUNX3: A Link between p53 Deficiency and MYC Dysregulation.致癌性 RUNX3：p53 缺失与 MYC 失调之间的联系。
Mol Cells. 2020 Feb 29;43(2):176-181. doi: 10.14348/molcells.2019.0285.
9
Making a Tissue Microarray.制作组织芯片。
Methods Mol Biol. 2019;1897:313-323. doi: 10.1007/978-1-4939-8935-5_27.
10
Inhibition of histone methyltransferase EZH2 in Schistosoma mansoni in vitro by GSK343 reduces egg laying and decreases the expression of genes implicated in DNA replication and noncoding RNA metabolism.GSK343 抑制曼氏血吸虫体内组蛋白甲基转移酶 EZH2 的活性可减少产卵，并降低参与 DNA 复制和非编码 RNA 代谢的基因的表达。
PLoS Negl Trop Dis. 2018 Oct 26;12(10):e0006873. doi: 10.1371/journal.pntd.0006873. eCollection 2018 Oct.